These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 34452691

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
    Stump DG, O'Connor JC, Lewis JM, Marty MS.
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
    Willett CE, Bishop PL, Sullivan KM.
    Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
    Browne P, Noyes PD, Casey WM, Dix DJ.
    Environ Health Perspect; 2017 Sep 01; 125(9):096001. PubMed ID: 28934726
    [Abstract] [Full Text] [Related]

  • 16. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
    Marty MS, O'Connor JC.
    Birth Defects Res B Dev Reprod Toxicol; 2014 Feb 01; 101(1):63-79. PubMed ID: 24515841
    [Abstract] [Full Text] [Related]

  • 17. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
    Borgert CJ.
    Crit Rev Toxicol; 2023 Feb 01; 53(2):53-68. PubMed ID: 37216681
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Xenoendocrine disrupters-tiered screening and testing: filling key data gaps.
    Gray LE, Ostby J, Wilson V, Lambright C, Bobseine K, Hartig P, Hotchkiss A, Wolf C, Furr J, Price M, Parks L, Cooper RL, Stoker TE, Laws SC, Degitz SJ, Jensen KM, Kahl MD, Korte JJ, Makynen EA, Tietge JE, Ankley GT.
    Toxicology; 2002 Dec 27; 181-182():371-82. PubMed ID: 12505339
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.